(Q36894729)

16 August 2017

title

Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist (English)

1 reference

16 August 2017

Sarhan S

1

1 reference

16 August 2017

Hitchcock JM

series ordinal

2

1 reference

16 August 2017

Grauffel CA

series ordinal

3

1 reference

16 August 2017

Wettstein JG

series ordinal

4

1 reference

16 August 2017

publication date

1 January 1997

1 reference

16 August 2017

1 reference

16 August 2017

volume

18

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

1223-1227

1 reference

Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Antinociceptive profile of sulfated CCK-8. Comparison with CCK-4, unsulfated CCK-8 and other neuropeptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Benz(f)isoquinolines as excitatory amino acid antagonists: an indication of their mechanism of action?

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

The development of catalepsy in drug-free mice on repeated testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin n.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

History and pharmacology of PCP and PCP-related analogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Induction of catalepsy by central nervous system administration of neurotensin

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Differential neurobehavioral effects of neurotensin and structural analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: Microdialysis combined with a sequential multiple antigen radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

The central stimulatory action of inhibitors of the dopamine uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Antagonism of phencyclidine-induced hyperactivity in mice by elevated brain GABA concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

Glutamate: a new target in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0196-9781%2897%2900145-9

7 January 2021

10.1016/S0196-9781(97)00145-9

Identifiers

DOI

1 reference

16 August 2017

1 reference